Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
REVIEW ARTICLE
Year : 2020  |  Volume : 30  |  Issue : 5  |  Page : 45-53

Cardiac tumors


1 Department of Cardiology, University of Foggia, Foggia, Italy
2 Department of Cardiology, Aviano Hospital, Pordenone, Aviano, Italy
3 Department of Radiology, University of Foggia, Foggia, Italy
4 Department of Cardiology, Como Hospital, Como, Italy
5 Department of Cardiology, Milano San Donato Hospital, Milano, Italy
6 Department of General Surgery and Medical.Surgery Specialities, University of Catania, Catania, Italy

Date of Submission14-Jan-2020
Date of Acceptance04-Oct-2020
Date of Web Publication10-Apr-2020

Correspondence Address:
Dr. Grazia Casavecchia
Department of Cardiology, University of Foggia, Foggia
Italy
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcecho.jcecho_7_19

Rights and Permissions
  Abstract 


Cardiac tumors (CTs) are extremely rare, with an incidence of approximately 0.02% in autopsy series. Primary tumors of the heart are far less common than metastatic tumors. CTs usually present with any possible clinical combination of heart failure, arrhythmias, or embolism. Echocardiography remains the first diagnostic approach when suspecting a CT which, on the other side, frequently appears unexpectedly during an echocardiographic examination. Yet, cardiac tomography and especially magnetic resonance imaging may offer several adjunctive opportunities in the diagnosis of CTs. Early and exact diagnosis is crucial for the following therapy and outcome of CTs.

Keywords: Atrial myxomas, cancer of the heart, cardiac tumors, computed tomography and magnetic resonance imaging of primary cardiac malignancies, echocardiography in the diagnosis of cardiac tumors, malignant tumors of the heart


How to cite this article:
Casavecchia G, Lestuzzi C, Gravina M, Corrado G, Tusa M, Brunetti ND, Manuppelli V, Monte IP. Cardiac tumors. J Cardiovasc Echography 2020;30, Suppl S1:45-53

How to cite this URL:
Casavecchia G, Lestuzzi C, Gravina M, Corrado G, Tusa M, Brunetti ND, Manuppelli V, Monte IP. Cardiac tumors. J Cardiovasc Echography [serial online] 2020 [cited 2021 Mar 8];30, Suppl S1:45-53. Available from: https://www.jcecho.org/text.asp?2020/30/5/45/282283




  Introduction Top


Cardiac tumors (CTs) are exceedingly rare. With an incidence of approximately 0.02% in autopsy series, primary tumors of the heart are far less common than metastatic tumors. Myxoma is the most common benign tumor (50%–70%); angiosarcoma is the most common malignant one (30%), followed by rhabdomyosarcoma (20%).[1],[2] About 10% of all tumor patients develop cardiac metastases, but these are only rarely clinically manifest.[3] Nonetheless, they may cause a wide variety of clinical signs and symptoms that often masquerade as many other more common cardiovascular and systemic diseases. Echocardiography remains the first diagnostic approach when suspecting a CT which, on the other side, frequently appears unexpectedly during an echocardiographic examination. Yet, computed tomography (CT) and especially magnetic resonance imaging (MRI) offer several adjunctive advantages that make these technologies the most sophisticated among the imaging techniques available today. An early and correct diagnosis may change the patient's clinical management and prognosis.


  Clinical Presentation Top


CTs usually present with some combination of heart failure, arrhythmias, or embolic phenomena. Intracavitary tumors are more likely to cause heart failure or embolic phenomena, whereas intramural tumors are more likely to cause arrhythmias. Nevertheless, also intracavitary tumors may have some point of attachment at the cardiac walls and thus can be arrhythmogenic; on the other hand, intramural tumors, if large enough, may bulge and partially obliterate a cardiac chamber or interfere with a ventricle's mechanical performance and thus cause heart failure. Therefore, the specific signs and symptoms produced by tumors are more closely related to their precise anatomical location, size, and relationships with the surrounding structures than to their histological type. Tumors localized in the region of the atria or atrioventricular valves may restrict the blood flow into the heart, mimicking stenosis of the mitral or tricuspid valve. Mobile, pedunculated neoplasms generally lead to paroxysmal heart failure, syncope, dyspnea, or embolism. Tumor infiltration into the ventricular walls may produce symptoms similar to hypertrophic or restrictive cardiomyopathy; the clinical presentation is dominated by heart failure.[4] At ECG, pseudoischemic changes may be evident in the corresponding leads [Figure 1].[5] Expansion into the superior vena cava (SVC) may result in SVC syndrome. Tumor infiltration of the neural pathways or of the conduction system can cause irregular heartbeat and especially atrioventricular block (this is particularly common for fibromas); in some cases, the first manifestation of a CT is sudden cardiac death. CTs are often diagnosed after the patient has suffered a stroke, an embolism of the peripheral vasculature, or a pulmonary artery embolism, caused by detached tumor tissue or mobilization of thrombotic deposits. The possibility of paradoxical embolisms should also be kept in mind. Therefore, all fragments of embolic material retrieved during diagnostic investigations should be subjected to histological analysis. In particular, myxomas tend to cause embolisms because of their gelatinous structure.[6],[7],[8],[9] Papillary fibroleastomas also have systemic embolism as the most common nical presentation.[7],[8]
Figure 1: Metastatic angiosarcoma infiltrating the right ventricular wall. Top: 2D-echo long axis view. Down: pseudoischemic anomalies on corresponding leads

Click here to view



  Classification Top


CTs are divided into benign, malignant, and intermediate tumors of uncertain behavior, with separate sections on germ cell tumors and tumors of the pericardium [Table 1] and [Table 2].[10]
Table 1: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart6

Click here to view
Table 2: Clinicopathologic Features of Primary Heart Tumors

Click here to view


Most primary CTs are benign in nature. Of these benign CTs, cardiac myxomas by far are the most common entities in adults and rhabdomyomas in the pediatric population.

Cardiac myxoma

Cardiac myxoma typically presenting between the ages of 30 and 60 years and more commonly in women.[7],[8],[9] Approximately, 75% of myxomas occur in the left atrium where the site of attachment is almost always in the region of the limbus of the fossa ovalis. Myxomas may occasionally be found on the posterior left atrial wall, but tumors presenting in this location should raise the suspicion of malignancy; typically intracavitary, solitary mobile, and pedunculated, myxomas may prolapse to various degrees into the mitral valve orifice, resulting in obstruction of blood flow from the left atrium to the left ventricle as well as mitral regurgitation. Embolic events occur in 30% of patients. Myxomas also may occur in the right atrium (15%–20%). Carney complex is an autosomal dominant pattern syndrome, in which atrial and noncardiac myxomas, schwannomas, and various endocrine tumors are present, along with various skin pigmentation abnormalities.[11]

Papillary fibroelastoma [Figure 2]

Papillary fibroelastoma (PFE) is the most common tumor of the cardiac valves; it is a benign papilloma of the endocardium with a highly mobile stalk and is more often singular than multiple [Figure 2]. PFEs are most commonly localized on the valves, primarily the aortic valve followed by the mitral valve, mainly in the downstream side, with dimensions between 2 and 40 mm. Larger PFEs are seen when they occur on the right-sided valves, and they have the potential to embolize to vital structures. Embolization may occur from the fragile papillary fronds of the mass itself or from thrombotic material formed on the tumor. Accordingly to recent guidelines, intravenous alteplase is not contraindicated and may be reasonable for patients with major acute ischemic stroke likely to produce severe disability and cardiac myxoma or PFE.[12] These tumors may mimic infective endocarditis.
Figure 2: Papillary Fibroelastoma, 67-year old patient after transient ischemic attack (30 days earlier). 2D (left) and 3D (right) transthoracic echocardiogram showing a round formation with soft consistence on the atrial side of septal leaflet of tricuspid valve, firstly and erroneously considered ad an endocardial vegetation

Click here to view


Lipomatous hypertrophy and lipomas

Lipomatous hypertrophy (LHAS) and lipomas arise from benign neoplastic proliferation of nature adipocytes. True lipomas are rare and can occur at any age and with equal frequency in both sexes. They range in diameter from 1 to 15 cm. Most tumors are sessile or polypoid and occur in the subendocardium or subepicardium and are usually enclosed in a capsule. LHIS classically involves the anterior or superior portion of the interatrial septum and spares the fossa ovalis. On average, the septum is thickened up to 2.5 cm. Clinically, LHIS is associated with a higher incidence of atrial arrhythmias, that is, correlated with the degree of hypertrophy. Massive lipomatous hypertrophy can cause obstruction of the SVC.

Rhabdomyomas

Rhabdomyomas are the most common CTs of children and infants. Evidence suggests that rhabdomyomas correspond to a focal hamartomatous accumulation of the striated cardiomyocytes, and it is not actually a neoplasm. Rhabdomyomas occur most frequently in the myocardium of the left ventricle or in the interventricular septum, and they are strongly associated with tuberous sclerosis and appear usually as small and lobulated intramural nodules, with diameters in the range of 2 mm to 2 cm. Typically, rhabdomyomas tend to regress spontaneously, and this occurs in 50% of patients.[13],[14]

Fibromas

Fibromas are benign connective tissue tumors derived from fibroblast that occurs predominantly in children and constitute the second most frequent type of primary CT occurring in the pediatric age group. Typically are large tumors ranging from 3 to 10 cm in diameter. They usually occur within the ventricular myocardium and much more frequently within the anterior free wall of the left ventricle or the interventricular septum than in the posterior let ventricular wall or right ventricle. Approximately 70% of fibromas are symptomatic, causing mechanical interference with intracardiac flow, ventricular systolic function, or conduction disturbances.

Hemangiomas

Hemangiomas are extremely rare accounting for 5%–10% of benign tumors. They may occur in any part of the heart but more commonly are found in the lateral wall of the left ventricle, the anterior wall of the right ventricle, or the interventricular septum. Most often, they are incidentally, detected during examinations done for other reasons.

Teratomas

Teratomas are generally observed in children and occur in the pericardium. They are often attached to the base of the great vessels (root of the aorta or the pulmonary trunk). About 90% are located in the anterior mediastinum; the rest, mainly in the posterior mediastinum.[15]

Malignant primary tumors include sarcomas, pericardial mesothelioma, and primary lymphomas

Sarcoma

Sarcoma is a rare type of cancer that occurs in adults, children, and teens. Sarcomas may occur at any age but are most common between the third and fifth decade. Almost 40% are angiosarcomas, have a striking predilection for the right atrium/right ventricle and pericardium, causing right ventricular inflow tract obstruction, pericardial tamponade, and lung metastasis. Other types include undifferentiated sarcoma (25%), malignant fibrous histiocytoma (11%–24%), leiomyosarcoma (8%–9%), fibrosarcoma, rhabdomyosarcoma, liposarcoma, and osteosarcoma; these types are more likely to originate in the left atrium, causing mitral valve obstruction and heart failure.

Primary lymphoma

Primary lymphoma is extremely rare. It occurs more frequently in patients with acquired immunodeficiency syndrome (AIDS) or other people with immunodeficiency. These tumors may infiltrate the cardiac walls and grow within the atrial and/or ventricular cavities; they usually grow rapidly and may cause heart failure, arrhythmias, tamponade, and superior vena cava (SVC) syndrome [Figure 3].[16],[17],[18],[19]
Figure 3: (a) 2D apical 3-chamber view; (b) 2D apical 4-chamber view. Pericardial effusion and infiltrative mass on left and right ventricular apex, suggestive for malignancy in hip liposarcoma, endometrial adenocarcinoma, and breast infiltrating carcinoma. Final diagnosis was lymphoma

Click here to view


Metastatic tumors

Metastases can reach the heart via the lymphatic way or through the arterial or venous circulation. Lymphatic spread is common for lung and breast cancers and for some sarcomas and lymphomas; it frequently causes pericardial effusion and may cause the so-called “tumor encasement of the heart,” with constriction pattern.[20],[21],[22] It is important to bear in mind the possibility of a tumor encasement (with or without effusion) in the patients presenting with suspected cardiac tamponade because pericardial drainage will be not effective to relieve symptoms. Intracoronary dissemination is common for leukemia, melanoma, and some lymphomas; the metastases are usually intramural, and cases of acute coronary syndrome have been described. Genitourinary tumors often invade the inferior vena cava, grow quickly in a symbiotic way with superimposed thrombus (the so-called “tumor thrombosis) and reach the right atrium.[23],[24] Melanoma is a tumor with a high propensity for cardiac involvement; lung and breast carcinoma, soft-tissue sarcoma, and renal cancer are also common sources of metastases to the heart.[25],[26] Leukemia and lymphoma often metastasize to the heart. Considering both the prevalence of the primary tumor and the propensity to metastasize, the most common secondary tumor of the heart observed in the clinical practice is lung carcinoma (35%–40%), followed by hematologic malignancies (10%–20%) and breast cancer (10%).[27]


  Diagnosis Top


Echocardiography

Echocardiography is usually the first diagnostic procedure. When a cardiac mass is detected on echocardiography, the differential diagnosis includes thrombi, benignant tumors, and malignant tumors. The following characteristics must be considered: site, implant, involvement of other structures, and echogenicity. A broad-based mass located in an enlarged left atrium in a patient with atrial fibrillation and/or severe mitral stenosis is likely to be a thrombus. Thrombi in the right chambers are usually an extension or embolus from a deep venous thrombosis; usually, they are serpentine-like and highly mobile.[28] The most common benign tumors (myxomas and PFEs) are pedunculated, and the insertion is in the majority of cases on the left side of the interatrial septum (myxomas) or a cardiac valve (fibroelastomas). Malignant tumors are often broad-based and may have multiple sites; the extension of an intracardiac or pericardial mass in a cardiac wall is usually a marker of malignancy. However, also rhabdomyomas and fibromas may grow within a ventricular wall. Echo contrast agents are useful to confirm the presence of an intracardiac mass and to characterize it further by virtue of the extent of contrast enhancement, which is a marker of vascularity and to assess the myocardial infiltration [Figure 4]. Accordingly, malignant and highly vascular tumors demonstrate hyperenhancement with contrast, whereas thrombi do not appear to enhance at all; myxomas tend to be partially enhanced.[29],[30],[31] Of note, the uptake of the contrast agent by a CT is usually delayed (several minutes after the injection) and persistent; the use of qualitative and quantitative analysis of the reperfusion time has been proven useful in the differential diagnosis.[32],[33] Low mechanical index contrast echocardiography is an easy, noninvasive cardiac imaging tool to assess cardiac mass vascularization. The degree of contrast enhancement and time to opacification are highly variable among cardiac masses and correspond to different extent of vascularization.[34]
Figure 4: Echocardiogram of cardiac lymphoma infiltrating the left ventricular wall and protruding into the left ventricular lumen, after contrast injection. The apical septum is partially spared from neoplastic infiltration and appears darker. The small residual left ventricular cavity appears brighter (contrast effect

Click here to view


The identification of tumor thrombosis is of utmost importance in planning the therapies and is better achieved, implementing the echocardiographic examination with sonography.[35]

Transesophageal echocardiography

Transesophageal echocardiography appears to be superior to transthoracic echocardiography when the cardiac mass is located in the atria. The potential advantages of transesophageal echocardiography include improved resolution of the tumor and its attachment, the ability to detect some masses not visualized by transthoracic echocardiography, and to examine the pulmonary veins, venae cavae, the infiltration of the pulmonary veins for the left atrial masses. It should be considered when the transthoracic study is suboptimal, and it is frequently used for intraoperative (transvenous biopsy or cardiac surgery) monitoring [Figure 5] and [Figure 6].[36],[37],[38]
Figure 5: TEE of right atrial angiosarcoma extendig to superior vena cava. 2D (left) and 3D (right) images (Courtesy of Dr. Rita Piazza)

Click here to view
Figure 6: Transvenous biopsy of right atrial angiosarcoma (see figure 5). TEE monitoring was used to assess the position of the bioptome (arrow) (Courtesy of Dr. Rita Piazza)

Click here to view


Three-dimensional echocardiography

Three-dimensional (3D) echocardiography, both transthoracic and transesophageal, allows for a more accurate analysis of the mass (site, dimensions) and of its relationship with the neighboring structures. An additional advantage of 3D echo is the possibility of obtaining new section planes on the recorded images, and – using the cropping capability – to identify necrotic areas within the mass.[39],[40] If a CT cannot be confirmed by echocardiography, further imaging procedures such as CT or MRI are employed.[41]

Gated cardiac CT can act in a complimentary role to the other modalities in the evaluation of a cardiac mass. CT can provide information, functional assessment, and tissue characterization. With ECG gating to minimize motion-related artifacts, high-speed multistrate equipment provides high-quality images with superior resolution (<1 mm) and the possibility of obtaining multiplanar and tridimensional reconstructions. CT provides a high degree of soft-tissue discrimination, which is helpful in defining the degree of myocardial infiltration. CT can also be used to assess for the presence of calcification, which may be useful in the diagnosis of fibromas, teratomas, rhabdomyomas, hemangiomae, and osteosarcomas. The administration of a contrast agent may clarify further the degree of intramural invasion and can differentiate a vascular tumor from an avascular thrombus. CT provides additional information when the echocardiographic data are equivocal and allows a more accurate evaluation of changes in the follow-up. The main limits of this technique are the use of ionizing radiation.[42]

Cardiovascular magnetic resonance

Cardiovascular magnetic resonance (CMR) will probably become a staple imaging technique for CTs for several reasons, including its excellent spatial and contrast resolution (with no radiation exposure) and its ability to obtain a wide field of view and to perform multiplanar imaging. CMR can identify, with high specificity, cardiac masses that do not require excision: pseudotumors, thrombi, lipomas, lipomatous hypertrophy, and PFEs. Most other CTs will require tissue diagnosis to aid in the establishment of a treatment plan.[43],[44],[45] T1-weighted and T2-weighted dual-inversion recovery fast spin–echo sequences offer detailed morphological information, with T1-weighted images providing excellent soft-tissue characterization and T2-weighted images providing superior tissue contrast and demonstration of fluid components. For Heterogeneous tumors such as myxomas and teratomas, studies have demonstrated an excellent correlation between MRI and pathological findings. Short inversion recovery sequence permits the suppression of fat signals, and therefore, is useful in detecting lipid-containing masses such as lipoma. Contrast enhancement with gadolinium provides information on the vascularity of the mass; it often allows for better delineation of tumor infiltration within the myocardium and assists in the differentiation of thrombus from tumor. Steady-state free precession sequences cine acquisitions provide excellent 3D visualization of cardiac function, valve motion, and structure, size, attachment to adjacent structures and mobility of cardiac masses. CMR is emerging as the imaging modality of choice for complex cardiac masses [Figure 7], [Figure 8], [Figure 9], [Figure 10], [Figure 11].[46],[47],[48]
Figure 7: cRMI: left, iso-intense in T1-TSE sequences; middle iper-intense in T2; right, PSIR with central hypo-intense core compatible with diagnosis of fibroelastoma (courtesy Dr. Matteo Gravina)

Click here to view
Figure 8: Lypoma, 60-year old woman, with poor acustic window echocardiogram. Up, cMRI showing rounded capsule formation in right atrium on interatrial septum. Down, hyper-intense in T1 sequence and hypo-intense in fat sat sequences compatible with lypoma (courtesy of Dr. Matteo Gravina)

Click here to view
Figure 9: Cardiac Fibroma, 51-year old man referred for dizziness, sweating and vomit, admitted to acute cardiac care unit with suspected acute coronary syndrome (a) Echocardiography apical 4-chamber view: the mass is not visible. (b) Echocardiography off axis view: oval mass of the left ventricular lateral wall (ref 39-40)

Click here to view
Figure 10: Cardiac fibroma. Upper, cMRI T2-weighted images 4-chamber and short axis view showing hypo-intense nodular mass in the mid-apical and inferior-lateral wall segments. Down-left, first-pass minimal enhancement with gadolinium. Down-right, late enhancement 4-chamber view, the mass appears as hyper-intense (ref 39-40)

Click here to view
Figure 11: Angiosarcoma, 68-year old male with history of chest pain and dyspnea. cMRI: Solid tissue with improved contrast enhancement, surrounding the superior vena cava and right atrium and leading to reduced expansion with pericardium thickening and minimal effusion (courtesy of Dr. Matteo Gravina)

Click here to view


Positron-emission tomography and positron-emission tomography/computed tomography

Positron-emission tomography (PET) and PET/CT give additional information on the metabolic activity of the mass. As tumors are typically in a relatively hypermetabolic state, PET imaging using a metabolic tracer such as 2-fluorine 18 fluoro-2-deoxy-D-glucose (18 FDG) has proven useful in detecting malignant tumors. Glucose metabolism is quantified by the maximum standardized uptake value (SUV). Malignant tumors usually have a high SUV, proportional to their proliferative index; a maximum SUV <3.5 suggests a benign lesion, while a value >10 is highly suggestive of malignancy.[49],[50] Using FDG-PET/CT, a sensitivity of over 90% in differentiating benign and malignant processes was achieved.[51] A major problem with18 FDG is the variable uptake by the myocardium, which might reduce the diagnostic accuracy in ventricular tumors.[52] A low-carbohydrate, fat-rich meal followed by a prolonged fasting period reduces the myocardial uptake of glucose and make possible to highlight CTs.[53] The intravenous injection of 50 Units/Kg of body weight of unfractioned heparin shortly before the injection of18 FDG further reduces the physiological myocardial uptake of glucose.[54]


  Treatment Top


The treatment of benign primary tumors (myxoma, PFEs, and lipoma) is surgical excision followed by serial echocardiography over 5–6 years to monitor for recurrence.[55] In about 1%–5% of cases, a recurrence or second cardiac myxoma has been reported after resection of the initial one. Rhabdomyomas regress spontaneously after infancy. The prognosis after surgery is usually excellent in the case of benign tumors.

Treatment of malignant primary tumors is surgery, with the goal of a complete resection without infiltrated margins; this is more difficult in large tumors infiltrating the ventricular walls and in angiosarcomas (only in 30% of cases a complete resection is possible).[56] A neoadjuvant (preoperatory) chemotherapy may improve the resectability of large tumors; for left atrial tumors, autotransplantation may be necessary to achieve a complete resection.[57] Chemotherapy and – in selected cases – local radiotherapy may be used after surgery; it is mandatory in all the cases of incomplete resection because the rate of recurrence is usually high and may prolong the time-to-relapse and the overall survival in the other patients.[58],[59] An accurate evaluation of the characteristic of malignant tumors (type, size, site, presence of metastases, and rese ctability) before planning any intervention is a mainstay of treatment.[60] Lymphomas are treated by steroids, systemic chemotherapy (and antiretroviral therapy in case of AIDS-related lymphomas).[61],[62],[63],[64]

Treatment of metastatic CTs depends on tumor origin. It is usually based on systemic chemotherapy. For solid tumors, mostly those from lung cancer, with pericardial metastases, intrapericardial chemotherapy increases the rate of complete cure and event-free survival.[65],[66] Tumor thrombosis may be treated with an association of chemotherapy and anticoagulants (low molecular weight heparin), but other options (insertion of a vena cava filter, thrombectomy, and closure of the IVC at the time of surgery) may be considered according to the clinical presentation.[67],[68]


  Conclusions Top


Primary CTs are mostly benign and have a good prognosis, whereas malignant primary CTs are most commonly sarcomas and have a poor prognosis. CTs may be misdiagnosed as other conditions (including rheumatic valvular disease, endocarditis, myocarditis, pericarditis, cardiomyopathies, and congenital heart disease), pulmonary conditions (including pulmonary emboli, pulmonary hypertension, and interstitial lung disease), cerebrovascular disease and vasculitis. Advances in noninvasive cardiovascular imaging techniques, especially echocardiography, CT and MRI have greatly facilitated the diagnostic evaluation and permit the rapid identification of intracardiac masses. A multidisciplinary approach is of paramount importance in defining the diagnosis and in planning therapies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Neragi-Miandoab S, Kim J, Vlahakes GJ. Malignant tumours of the heart: A review of tumour type, diagnosis and therapy. Clin Oncol (R Coll Radiol) 2007;19:748-56.  Back to cited text no. 1
    
2.
Rizzo S, Thiene G, Valente M, Basso C. Primary cardiac malignancies: Epidemiology and pathology. In: Lestuzzi C, Oliva S, Ferraù F, editors. Manual of Cardioncology: Springer; 2017. p. 339-65.  Back to cited text no. 2
    
3.
Sarjeant JM, Butany J, Cusimano RJ. Cancer of the heart: Epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs 2003;3:407-21.  Back to cited text no. 3
    
4.
Pino P, Lestuzzi C. Cardiac malignancies. Clinical aspects. In: Lestuzzi C, Oliva S, Ferraù F, editors. Manual of Cardioncology: Springer; 2017. p. 311-8.  Back to cited text no. 4
    
5.
Lestuzzi C, Nicolosi GL, Biasi S, Piotti P, Zanuttini D. Sensitivity and specificity of electrocardiographic ST-T changes as markers of neoplastic myocardial infiltration. Echocardiographic correlation. Chest 1989;95:980-5.  Back to cited text no. 5
    
6.
St John Sutton MG, Mercier LA, Giuliani ER, Lie JT. Atrial myxomas: A review of clinical experience in 40 patients. Mayo Clin Proc 1980;55:371-6.  Back to cited text no. 6
    
7.
Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. Medicine (Baltimore) 2001;80:159-72.  Back to cited text no. 7
    
8.
Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T, et al. Cardiac tumours: Diagnosis and management. Lancet Oncol 2005;6:219-28.  Back to cited text no. 8
    
9.
Hoppe UC, La Rosee K, Beuckelmann DJ, Erdmann E. Herztumoren – Manifestation durch uncharakteristische Symptomatik Heart tumors—their manifestation through uncharacteristic symptoms. Dtsch Med Wochenschr 1997;122:551-7.  Back to cited text no. 9
    
10.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: International Agency for Research on Cancer; 2015.  Back to cited text no. 10
    
11.
Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985;64:270-83.  Back to cited text no. 11
    
12.
Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A Statement for healthcare professionals from the American heart association/American stroke association. Stroke 2016;47:581-641.  Back to cited text no. 12
    
13.
Jain D, Maleszewski JJ, Halushka MK. Benign cardiac tumors and tumorlike conditions. Ann Diagn Pathol 2010;14:215-30.  Back to cited text no. 13
    
14.
Günther T, Schreiber C, Noebauer C, Eicken A, Lange R. Treatment strategies for pediatric patients with primary cardiac and pericardial tumors: A 30-year review. Pediatr Cardiol 2008;29:1071-6.  Back to cited text no. 14
    
15.
Cox JN, Friedli B, Mechmeche R, Ismail MB, Oberhaensli I, Faidutti B, et al. Teratoma of the heart. A case report and review of the literature. Virchows Arch A Pathol Anat Histopathol 1983;402:163-74.  Back to cited text no. 15
    
16.
Chalabreysse L, Berger F, Loire R, Devouassoux G, Cordier JF, Thivolet-Bejui F. Primary cardiac lymphoma in immunocompetent patients: A report of three cases and review of the literature. Virchows Arch 2002;441:456-61.  Back to cited text no. 16
    
17.
Fuzellier JF, Saade YA, Torossian PF, Baehrel B. Primary cardiac lymphoma: Diagnosis and treatment. Report of 6 cases and review of the literature. Arch Mal Coeur Vaiss 2005;98:875-80.  Back to cited text no. 17
    
18.
Nascimento AF, Winters GL, Pinkus GS. Primary cardiac lymphoma: Clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder. Am J Surg Pathol 2007;31:1344-50.  Back to cited text no. 18
    
19.
Chin JY, Chung MH, Kim JJ, Lee JH, Kim JH, Maeng IH, et al. Extensive primary cardiac lymphoma diagnosed by percutaneous endomyocardial biopsy. J Cardiovasc Ultrasound 2009;17:141-4.  Back to cited text no. 19
    
20.
Tamura A, Matsubara O, Yoshimura N, Kasuga T, Akagawa S, Aoki N. Cardiac metastasis of lung cancer. A study of metastatic pathways and clinical manifestations. Cancer 1992;70:437-42.  Back to cited text no. 20
    
21.
Lee DS, Barnard M, Freeman MR, Hutchison SJ, Graham AF, Chiu B. Cardiac encasement by metastatic myxoid liposarcoma. Cardiovasc Pathol 2002;11:322-5.  Back to cited text no. 21
    
22.
Ibrahim N, Lopez-Candales A. Cement encasement of the pericardium: Echocardiographic manifestation. BMJ Case Rep 2014;2014: pii: bcr2014205276.  Back to cited text no. 22
    
23.
Shamberger RC, Ritchey ML, Haase GM, Bergemann TL, Loechelt-Yoshioka T, Breslow NE, et al. Intravascular extension of wilms tumor. Ann Surg 2001;234:116-21.  Back to cited text no. 23
    
24.
Lall A, Pritchard-Jones K, Walker J, Hutton C, Stevens S, Azmy A, et al. Wilms' tumor with intracaval thrombus in the UK children's cancer study group UKW3 trial. J Pediatr Surg 2006;41:382-7.  Back to cited text no. 24
    
25.
Glancy DL, Roberts WC. The heart in malignant melanoma. A study of 70 autopsy cases. Am J Cardiol 1968;21:555-71.  Back to cited text no. 25
    
26.
Klatt EC, Heitz DR. Cardiac metastases. Cancer 1990;65:1456-9.  Back to cited text no. 26
    
27.
Goldberg AD, Blankstein R, Padera RF. Tumors metastatic to the heart. Circulation 2013;128:1790-4.  Back to cited text no. 27
    
28.
Kronik G. The European cooperative study on the clinical significance of right heart thrombi. Eur Heart J 1989;12:1046-59.  Back to cited text no. 28
    
29.
Baumgartner RA, Das SK, Shea M, LeMire MS, Gross BH. The role of echocardiography and CT in the diagnosis of cardiac tumors. Int J Card Imaging 1988;3:57-60.  Back to cited text no. 29
    
30.
Mansencal N, Revault-d'Allonnes L, Pelage JP, Farcot JC, Lacombe P, Dubourg O. Usefulness of contrast echocardiography for assessment of intracardiac masses. Arch Cardiovasc Dis 2009;102:177-83.  Back to cited text no. 30
    
31.
Kirkpatrick JN, Wong T, Bednarz JE, Spencer KT, Sugeng L, Ward RP, et al. Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging. J Am Coll Cardiol 2004;43:1412-9.  Back to cited text no. 31
    
32.
Lestuzzi C. Primary tumors of the heart. Curr Opin Cardiol 2016;31:593-8.  Back to cited text no. 32
    
33.
Uenishi EK, Caldas MA, Tsutsui JM, Abduch MC, Sbano JC, Kalil Filho R, et al. Evaluation of cardiac masses by real-time perfusion imaging echocardiography. Cardiovasc Ultrasound 2015;13:23.  Back to cited text no. 33
    
34.
Barchitta A, Basso C, Piovesana PG, Antonini-Canterin F, Ruzza L, Bianchi A, et al. Opacification patterns of cardiac masses using low-mechanical index contrast echocardiography: Comparison with histopathological findings. Cardiovasc Pathol 2017;30:72-7.  Back to cited text no. 34
    
35.
Wang J, Cheng Y, Lee YZ, Wang Y, Zheng Y, Dong R, et al. Sonography and transthoracic echocardiography for diagnosis of systemic cardiovascular metastatic tumor thrombi. J Ultrasound Med 2016;35:1993-2027.  Back to cited text no. 35
    
36.
Peters PJ, Reinhardt S. The echocardiographic evaluation of intracardiac masses: A review. J Am Soc Echocardiogr 2006;19:230-40.  Back to cited text no. 36
    
37.
Takaya T, Takeuchi Y, Nakajima H, Nishiki-Kosaka S, Hata K, Kijima Y, et al. Usefulness of transesophageal echocardiographic observation during chemotherapy for cardiac metastasis of non-Hodgkin lymphoma complicated with left ventricular diastolic collapse. J Cardiol 2009;53:447-52.  Back to cited text no. 37
    
38.
Jurkovich D, de Marchena E, Bilsker M, Fierro-Renoy C, Temple D, Garcia H, et al. Primary cardiac lymphoma diagnosed by percutaneous intracardiac biopsy with combined fluoroscopic and transesophageal echocardiographic imaging. Catheter Cardiovasc Interv 2000;50:226-33.  Back to cited text no. 38
    
39.
Zaragoza-Macias E, Chen MA, Gill EA. Real time three-dimensional echocardiography evaluation of intracardiac masses. Echocardiography 2012;29:207-19.  Back to cited text no. 39
    
40.
Plana JC. Three-dimensional echocardiography in the assessment of cardiac tumors: The added value of the extra dimension. Methodist Debakey Cardiovasc J 2010;6:12-9.  Back to cited text no. 40
    
41.
Baumgartner RA, Das SK, Shea M, LeMire MS, Gross BH. The role of echocardiography and CT in the diagnosis of cardiac tumors. Int J Card Imaging 1988;3:57-60.  Back to cited text no. 41
    
42.
Lestuzzi C, De Paoli A, Baresic T, Miolo G, Buonadonna A. Malignant cardiac tumors: Diagnosis and treatment. Future Cardiol 2015;11:485-500.  Back to cited text no. 42
    
43.
Hoey ET, Mankad K, Puppala S, Gopalan D, Sivananthan MU. MRI and CT appearances of cardiac tumours in adults. Clin Radiol 2009;64:1214-30.  Back to cited text no. 43
    
44.
Gilkeson RC, Chiles C. MR evaluation of cardiac and pericardial malignancy. Magn Reson Imaging Clin N Am 2003;11:173-86, 8.  Back to cited text no. 44
    
45.
Gravina M, Casavecchia G, Totaro A, Ieva R, Macarini L, Di Biase M, et al. Left ventricular fibroma: What cardiac magnetic resonance imaging may add? Int J Cardiol 2014;176:e63-5.  Back to cited text no. 45
    
46.
Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ, et al. Cardiac papillary fibroelastoma: A comprehensive analysis of 725 cases. Am Heart J 2003;146:404-10.  Back to cited text no. 46
    
47.
Araoz PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. Radiographics 1999;19:1421-34.  Back to cited text no. 47
    
48.
Grebenc ML, Rosado de Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: Radiologic-pathologic correlation. Radiographics 2000;20:1073-103.  Back to cited text no. 48
    
49.
Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med 2012;53:856-63.  Back to cited text no. 49
    
50.
Kikuchi Y, Oyama-Manabe N, Manabe O, Naya M, Ito YM, Hatanaka KC, et al. Imaging characteristics of cardiac dominant diffuse large B-cell lymphoma demonstrated with MDCT and PET/CT. Eur J Nucl Med Mol Imaging 2013;40:1337-44.  Back to cited text no. 50
    
51.
Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT. Radiographics 2011;31:1287-305.  Back to cited text no. 51
    
52.
Maurer AH, Burshteyn M, Adler LP, Gaughan JP, Steiner RM. Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography: Importance for differentiating normal physiology from cardiac and paracardiac disease. J Thorac Imaging 2012;27:263-8.  Back to cited text no. 52
    
53.
Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M, et al. Significant suppression of myocardial (18) F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314-9.  Back to cited text no. 53
    
54.
Masuda A, Naya M, Manabe O, Magota K, Yoshinaga K, Tsutsui H, et al. Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart. Acta Radiol 2016;57:661-8.  Back to cited text no. 54
    
55.
Wang JG, Wang B, Hu Y, Liu JH, Liu B, Liu H, et al. Clinicopathologic features and outcomes of primary cardiac tumors: A 16-year-experience with 212 patients at a chinese medical center. Cardiovasc Pathol 2018;33:45-54.  Back to cited text no. 55
    
56.
Vaporciyan A, Reardon MJ. Right heart sarcomas. Methodist Debakey Cardiovasc J 2010;6:44-8.  Back to cited text no. 56
    
57.
Blackmon SH, Patel AR, Bruckner BA, Beyer EA, Rice DC, Vaporciyan AA, et al. Cardiac autotransplantation for malignant or complex primary left-heart tumors. Tex Heart Inst J 2008;35:296-300.  Back to cited text no. 57
    
58.
Leja MJ, Shah DJ, Reardon MJ. Primary cardiac tumors. Tex Heart Inst J 2011;38:261-2.  Back to cited text no. 58
    
59.
Isambert N, Ray-Coquard I, Italiano A, Rios M, Kerbrat P, Gauthier M, et al. Primary cardiac sarcomas: A retrospective study of the french sarcoma group. Eur J Cancer 2014;50:128-36.  Back to cited text no. 59
    
60.
De Paoli A, Miolo GM, Buonadonna A. Cardiac tumors: multimodality approach, follow-up, prognosis. In: Lestuzzi C, Oliva S, Ferraù F, editors. Manual of Cardioncology: Springer; 2017. p. 417-22.  Back to cited text no. 60
    
61.
Soon G, Ow GW, Chan HL, Ng SB, Wang S. Primary cardiac diffuse large B-cell lymphoma in immunocompetent patients: Clinical, histologic, immunophenotypic, and genotypic features of 3 cases. Ann Diagn Pathol 2016;24:40-6.  Back to cited text no. 61
    
62.
Lestuzzi C, Spina M, Martellotta F, Carbone A. Massive myocardial infiltration by HIV-related non-Hodgkin lymphoma: Echocardiographic aspects at diagnosis and at follow-up. J Cardiovasc Med (Hagerstown) 2012;13:836-8.  Back to cited text no. 62
    
63.
Chen CF, Hsieh PP, Lin SJ. Primary cardiac lymphoma with unusual presentation: A report of two cases. Mol Clin Oncol 2017;6:311-4.  Back to cited text no. 63
    
64.
Mauricio R, Mgbako O, Buntaine A, Moreira A, Jung A. Complete resolution of tumor burden of primary cardiac non-Hodgkin's lymphoma. Case Rep Cardiol 2016;2016:2124975.  Back to cited text no. 64
    
65.
Lestuzzi C. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. World J Cardiol 2010;2:270-9.  Back to cited text no. 65
    
66.
Lestuzzi C, Bearz A, Lafaras C, Gralec R, Cervesato E, Tomkowski W, et al. Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer 2011;72:340-7.  Back to cited text no. 66
    
67.
Cristofani LM, Duarte RJ, Almeida MT, Odone Filho V, Maksoud JG, Srougi M, et al. Intracaval and intracardiac extension of wilms' tumor. The influence of preoperative chemotherapy on surgical morbidity. Int Braz J Urol 2007;33:683-9.  Back to cited text no. 67
    
68.
Ayyathurai R, Garcia-Roig M, Gorin MA, González J, Manoharan M, Kava BR, et al. Bland thrombus association with tumour thrombus in renal cell carcinoma: Analysis of surgical significance and role of inferior vena caval interruption. BJU Int 2012;110:E449-55.  Back to cited text no. 68
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9], [Figure 10], [Figure 11]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Clinical Present...
Classification
Diagnosis
Treatment
Conclusions
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed748    
    Printed25    
    Emailed0    
    PDF Downloaded81    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]